ReviewHematology. American Society of Hematology. Education Program2015
Sickle cell trait diagnosis: clinical and social implications.
Review in Hematology. American Society of Hematology. Education Program, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 4 syntheses or guidelines pooled it, 147 citations in OpenAlex.
- Phenome- and laboratory-wide meta-analyses of sickle cell trait reveal multi-system disease associations.American journal of human genetics · 2026Pooled it
- Chronic kidney disease in adults with sickle cell trait: a systematic review and meta-analysis.Blood advances · 2025Pooled it
- Ancestry-independent risk of venous thromboembolism in individuals with sickle cell trait vs factor V Leiden.Blood advances · 2024Pooled it
- Clinical Outcomes Associated With Sickle Cell Trait: A Systematic Review.Annals of internal medicine · 2018Pooled it
- Trial
- Review
- Newborn Screening for Hemoglobinopathies and Thalassemias: Brief History, Recent Activities, and Global Status-2026.International journal of neonatal screening · 2026Review
- When sickle cell trait is not just trait: risk of VTE.Hematology. American Society of Hematology. Education Program · 2025Review
- Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT).Environmental and molecular mutagenesis · 2025Review
- Health-Related Quality of Life, Illness Perception, Stigmatization and Optimism Among Hematology Patients: Two Exploratory Path Models.Medicina (Kaunas, Lithuania) · 2025Article
- Tourniquet use in patients with sickle cell trait (SCT): Mediterranean or African ancestry influences complications, demonstrating a higher prevalence than control patients: matched study of nine hundred and forty SCT versus one thousand, two hundred and sixty three non-SCT patients.International orthopaedics · 2025Article
- The Prevalence and Predictors of Sickle Cell Anemia in the Saudi Arabia General Population: Findings from a Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2025Article
- Article
- Article
- Evolving Landscape of Sickle Cell Anemia Management in Africa: A Critical Review.Tropical medicine and infectious disease · 2024Review
- Assessing the Impact of Hematological Changes in Pregnancy on Maternal and Fetal Death: A Narrative Review.Cureus · 2024Review
- Article
- Differential sensitivity to hypoxia enables shape-based classification of sickle cell disease and trait blood samples at point of care.Bioengineering & translational medicine · 2024Article
- Prevalence, Risk Factors, and Complications of Sickle Cell Disease in Saudi Arabia: A Systematic Review.Cureus · 2024Review
- Sickle Cell Screening in Adults: A Current Review of Point-of-Care Testing.Journal of hematology · 2024Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The sickle hemoglobin (HbS) point mutation has independently undergone evolutionary selection at least five times in the world because of its overwhelming malarial protective effects in the heterozygous state. In 1949, homozygous Hb S or sickle cell disease (SCD) became the first inherited condition identified at the molecular level; however, since then, both SCD and heterozygous Hb S, sickle cell trait (SCT), have endured a long and complicated history. Hasty adoption of early mass screening programs for SCD, recent implementation of targeted screening mandates for SCT in athletics, and concerns about stigmatization have evoked considerable controversy regarding research and policy decisions for SCT. Although SCT is a largely protective condition in the context of malaria, clinical sequelae, such as exercise-related injury, renal complications, and venous thromboembolism can occur in affected carriers. The historical background of SCD and SCT has provided lessons about how research should be conducted in the modern era to minimize stigmatization, optimize study conclusions, and inform genetic counseling and policy decisions for SCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.